{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-001494","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.562949+00:00","generated_at":"2026-05-24T01:39:16.505564+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances","bullets":["Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.","Cash and equivalents $9.9M as of Dec 31 2024, down from $26.4M a year earlier; working capital $9.2M.","Plans to initiate norovirus human challenge study in U.S. in 2025 for oral pan-viral protease inhibitor CDI-988.","Will continue Phase 2a influenza challenge study of CC-42344 after low infection rate precluded efficacy data.","Expects topline results from CDI-988 high-dose cohort in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-001494","json":"https://secwatch.observer/filing/0001641172-25-001494.json","markdown":"https://secwatch.observer/filing/0001641172-25-001494.md","text":"https://secwatch.observer/filing/0001641172-25-001494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/0001641172-25-001494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:39:16.505564+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}